CCDC88A and hepatocellular carcinoma: Development of the chimeric monoclonal antibody HAb18 from BALB/c mice immunized with CD147+ human HCC tissue showed a 99.55% binding rate against human antigen CD147/HAb18G with evident FAK-PI3K-Akt-Girdin pathway-mediated tumor-specific cytotoxicity (103, 105).